Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 4, 1996, Pages 313-325

  Mummaneni, Vanaja ^a   Kaul, Sanjeev ^a   Igwemezie, Linus N ^a   Newell, David R ^b   Porter, David ^b   Thomas, Huw ^b   Calvert, A Hilary ^b   Winograd, Benjamin ^a   Barbhaiya, Rashmi H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bioequivalent; Cancer; Etoposide; Etoposide phosphate; Humans; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ETOPOFOS; ETOPOSIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CROSS-OVER STUDIES; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; PRODRUGS; THERAPEUTIC EQUIVALENCY;

EID: 0030499603     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353515     Document Type: Article

References (22)

1. P. J. O'Dwyer, B. Leyland-Jones, M. T. Alonso, S. Marsoni, and R. E. Wittes. Etoposide (VP-16-213), Current status of an active anticancer drug. New Engl. J. Med. 312:692 699 (1985).
2. M. M. Hudson, H. J. Weinstein, S. S. Donaldson, C. Greenwald, L. Kun, N. J. Tarbell, W. A. Humphrey, C. Rupp, N. M. Marina, J. Wilimas, and M. P. Link. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J. Clin. Oncol. 11:1080-1084 (1993).
3. C. A. Linker, C. A. Ries, L. E. Damon, H. S. Rugo, and J. L. Wolf. Autologous bone marrow transplantation for acute myeloid leukemia using husulfan plus etoposide as a preparative regimen. Blood 81:311-318 (1993).
4. A. M. Gianni, M. Bregni, S. Siena, M. Magni, M. De-Nicola, F. Lombardi, C. Tarella, A. Pileri, and G. Bonadonna. Granulocyte-rnacrophage colony stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J. Clin. Oncol. 10:1955-1962 (1992).
5. N. J. Chao, A. S. Stein, G. D. Long, R. S. Negrin, M. D. Amylon, R. M. Wong, S. J. Forman, and K. G. Blume. Busulfan/Etoposide-Initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 81:319-323 (1993).
6. T. L. Schwinghammer, M. Reilly, and C. S. Rosenfeld. Cracking of ABS plastic devices used to infuse undiluted etoposide injection [Letter]. Am. J. Hosp. Pharm. 45:1277 (1988).
7. D. R. Budman, L. N. Igwemezie, S. Kaul, J. Behr, S. Lichtman, P. Schulman, V. Vinciguerra, S. L. Allen, J. Kolitz, K. Hock, K. O'Neill, L. Schacter, and R. H. Barbhaiya. Phase I evaluation of water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. J. Clin. Oncol. 12:1902-1909 (1994).
8. L. N. Igwemezie, S. Kaul, and R. H. Barbhaiya. Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. Pharm. Res. 12:117-123 (1994).
9. M. J. Milward, D. R. Newell, K. Balmanno, C. J. Charlton, L. Gumbrell, M. J. Lind, F. Chapman, M. Proctor, D. Simmonds, B. Cantwell, G. A. Taylor, C. McDaniel, B. Winograd, and A. H. Calvert. Clinical and pharmacokinetic study of BMY-40481. (Abstract). Proc. Am. Assoc. Cancer Res. 33:529 (1992).
10. S. Z. Fields, L. N. Igwemezie, S. Kaul, L. P. Schacter, R. J. Schilder, P. P. Litam, B. S. Himpler, C. McAleer, J. Wright, R. H. Barbhaiya, C. J. Langer, and P. O'Dwyer. Phase I study of etoposide phosphate (Etopophos) as a 30-min infusion on days 1, 3, and 5. Clin. Cancer Res. 1:105-111 (1995).
11. D. S. Thompson, F. A. Greco, A. A. Miller, N. R. Srinivas, L. N. Igwemezie, J. D. Hainsworth, L. P. Schacter, S. Kaul, R. H. Barbhaiya, G. C. Garrow, and K. D. Hande. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clin. Pharmacol. Ther. 57:499-507 (1995).
12. M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Dekker, New York, 1982.
13. M. Weiss. A general model of metabolite kinetics following intravenous and oral administration of the parent drug. Biopharm. Drug Dispos. 9:159-176 (1988).
14. G. E. P. Box and D. R. Cox. Analysis of transformations. J. Roy. Stat. Soc. B. 26:211-252 (1964).
15. D. J. Schuirmann. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokin. Biopharm. 15:657-680 (1987).
16. V. W. Steinijans and D. Hauschke. International harmonization of regulatory bioequivalence requirements. Clin. Res. Reg. Affairs. 10:203-220 (1993).
17. SAS Institute. SAS User's Guide: Statistics Version 5.18, 5th ed., SAS Institute, Cary, NC, 1985.
18. B. P. McGrath, R. W. Watts, and D. B. Elmfeldt. Clinical equivalence of two tablet formulations of feldopine: A placebo controlled study of 24-hour blood pressure control and tolerability. Eur. J. Clin. Pharmacol. 49:169-172 (1995).
19. S. Kaul, L. N. Igwemezie, D. J. Stewart, S. Z. Fields, M. Kosty, N. Levithan, R. Bukowski, D. Gandara, G. Goss, P. O'Dwyer, L. P. Schacter, and R. H. Barbhaiya. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J. Clin. Oncol. 13:2835-2841 (1995).
20. A. A. Miller, C. F. Stewart, and E. A. Trolley. Clinical pharmacodynamics of continuous infusion etoposide. Cancer Chemother. Pharmacol. 25:361-366 (1990).
21. C. F. Stewart, S. G. Arbuck, R. A. Fleming, and W. E. Evans. Relationship of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther. 50:385-393 (1991).
22. M. J. Milward, D. R. Newell, V. Mummaneni, L. N. Igwemezie, K. Balmanno, C. J. Charlton, L. Gumbrell, M. J. Lind, F. Chapman, M. Proctor, D. Simmonds, B. M. J. Cantwell, G. A. Taylor, C. McDaniel, B. Winograd, S. Kaul, R. H. Barbhaiya, and A. H. Calvert. Phase I and pharmacokinetic study of a water soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur. J. Cancer 13A:2409-2411 (1995).